TARO-ACYCLOVIR OINTMENT

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

ACYCLOVIR

זמין מ:

TARO PHARMACEUTICALS INC

קוד ATC:

D06BB03

INN (שם בינלאומי):

ACICLOVIR

כמות:

5%

טופס פרצבטיות:

OINTMENT

הרכב:

ACYCLOVIR 5%

מסלול נתינה (של תרופות):

TOPICAL

יחידות באריזה:

15G/50G

סוג מרשם:

Prescription

איזור תרפויטי:

ANTIVIRALS

leaflet_short:

Active ingredient group (AIG) number: 0115506007; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2021-11-09

מאפייני מוצר

Page 1 of 33
PRODUCT
MONOG
RAP
H
PR
TARO-ACYCLOVIR
Acy
clovi
r Ointment, USP
5% w/w
ANTIVIRAL AGENT
Date of Preparation:
November 08, 2021
Taro Pharmaceuticals Inc.
130 East Drive,
Brampton, Ontario
Canada L6T 1C1
Control #: 251289
Page 2 of 33
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
................................................................................
3
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
...............................................................................................................................
5
PRECAUTIONS
.........................................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
6
ADVERSE REACTIONS
...........................................................................................................
6
SYMPTOMS AND TREATMENT OF OVERDOSAGE
.......................................................... 7
DOSAGE AND ADMINISTRATION
.......................................................................................
7
PHARMACEUTICAL INFORMATION
..................................................................................
8
AVAILABILITY OF DOSAGE FORMS
..................................................................................
9
STORAGE CONDITIONS
.........................................................................................................
9
VIROLOGY
...............................................................................................................................
9
PHARMACOLOGY
.........................................................................